Skip to Main Content

Translational-Targeted Area of Research Excellence (T-TARE) Awards

The Yale Cancer Center T-TARE Program provides support of up to $200,000 for groups headed by a member of the Cancer Center, for research with a significant translational or clinical component, with the express purpose of developing a multi-investigator grant submission to the National Cancer Institute, such as a Program Project Grant or SPORE grant. The primary objectives of the T-TARE awards are to promote translational research and to facilitate collaborations between physicians and scientists. Consistent with these objectives, the review process of the proposals will be collaborative among physicians and scientists.

Review criteria:
1. Potential for project developing into a multi-investigator grant proposal within one year
2. Translational potential (overall and within three year time period)
3. Scientific merit/clinical feasibility
4. Strength of collaborative team (scientific strength, successful funding/publication record, commitment to clinical investigation, prior evidence of team interaction)
5. Strength of senior leadership (funding/publication track record)

For more information on the T-TARE Awards, please contact Anna Arnal Estapé, PhD.



Scalability study for Automated Clinical Trial Patient Matching System

Pamela Kunz, MD and Guannan Gong, PhD


Mechanisms and Biomarkers for Combinatorial Treatment of Solid Tumors with BETi and HDACi

Qin Yan, PhD, and Patricia LoRusso, DO



A pilot study of interventions to increase adherence to cervical cancer early detection and treatment recommendations in Connecticut

Donna Spiegelman, ScD and Sangini Sheth, MD, MPH



CXCR5-targeted CAR-T for Aggressive T Cell Lymphomas

Elias Lolis, PhD, Samuel Katz, MD, PhD, Francine Foss, MD, and Jason Cai, PhD



Yale Brain SPORE Team

Murat Gunel, MD, and Antonio Omuro, MD


Optimization of Cellular Immunotherapy for Melanoma

Marcus Bosenberg, MD, PhD, and Samuel Katz, MD, PhD



Novel therapies and targets in head and neck cancer

Barbara Burtness, MD


DNA repair as a target for cancer therapies

Patricia LoRusso, DO and Joann Sweasy, PhD



Expanding Therapeutic Options for Triple Negative Breast Cancer

Lajos Pusztai, MD, DPhil


Divide and Conquer: Advancing Therapy for Head and Neck Squamous Cell Carcinoma

Wendell Yarbrough, MD


Next Generation Targeting of Oncogenes in the Tumor Microenvironment

Frank Slack, PhD



The biology and treatment of primary and metastatic lung cancer

Roy S. Herbst, MD, PhD


Comprehensive approaches for understanding and treating melanoma brain metastases

Harriet Kluger, MD


Translation of convection-enhanced delivery of drug-loaded nanoparticles for treatment of glioma

W. Mark Saltzman, PhD and Joseph Piepmeier, MD